Novozymes A/S (OTCMKTS:NVZMY) Stock Short Interest Climbs 1,986.3%

Novozymes A/S (OTCMKTS:NVZMY) was the target of a large increase in short interest in October. As of October 15th, there was short interest totaling 11,391 shares, an increase of 1,986.3% from the September 30th total of 546 shares. Based on an average daily volume of 47,751 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B increased its stake in shares of Novozymes A/S (OTCMKTS:NVZMY) by 73.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Novozymes A/S Price Performance

Shares of NVZMY opened at $70.12 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.04 and a current ratio of 1.74. The company has a 50 day moving average price of $67.47 and a 200-day moving average price of $62.46. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.27. The stock has a market capitalization of $29.07 billion, a PE ratio of 44.38, a PEG ratio of 3.23 and a beta of 0.89.

Novozymes A/S (OTCMKTS:NVZMY) last issued its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.16). The business had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Novozymes A/S had a net margin of 14.70% and a return on equity of 6.54%. Equities analysts predict that Novozymes A/S will post 2.45 earnings per share for the current fiscal year.

Novozymes A/S Company Profile

Novozymes A/S was a Denmark-based biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its products were designed to help customers improve manufacturing processes, reduce resource consumption and develop more sustainable alternatives to conventional chemicals and production methods.

The company served a broad range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.